9/19/2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 19, 2025--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time.

Source: Yahoo

9/19/2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Source: Yahoo

9/19/2025

United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the index over the past six months as its stock price is up 29.3%.

Source: Yahoo

9/16/2025

We came across a bullish thesis on Liquidia Corporation on wallstreetbets subreddit by robbinhood69. In this article, we will summarize the bulls’ thesis on LQDA. Liquidia Corporation’s share was trading at $27.80 as of September 9th. Liquidia (LQDA) has delivered a strong debut for its recently launched drug, marking a milestone after years of delays tied to […]

Source: Yahoo

9/16/2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 16, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York.

Source: Yahoo

9/12/2025

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 12, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October 1, 2025.

Source: Yahoo

9/11/2025

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

9/10/2025

Shares of United Therapeutics stock shot up 33% on Sept. 2 to an all-time high after the company announced positive results for its drug, Tyvaso. Tyvaso treats patients with a chronic lung disease called idiopathic pulmonary fibrosis. Among its other key ratings United Therapeutics carries an 84 EPS Rating out of 99. United Therapeutics develops treatments for heart diseases and cancer.

Source: Yahoo

9/9/2025

Are you eyeing United Therapeutics and wondering if it still has room to run or if you’ve missed the train? You’re not alone. The stock has caught serious attention lately, with a remarkable 29.5% jump in just the last week and over 30% in the past month. That short-term surge comes on top of an impressive long-term climb: we’re talking 77.8% over three years and a massive 276.4% gain in five. If you’re looking for stability, even its year-to-date return stands at a solid 9.5%, well ahead of...

Source: Yahoo

9/8/2025

Discover United Therapeutics' breakthrough TETON 2 IPF trial results, market expansion

Source: SeekingAlpha

9/8/2025

It’s not every day that a partnership update gets investors talking, but that’s exactly what happened with MannKind (MNKD) this week. The company just announced an amendment to its license and collaboration agreement with United Therapeutics, which expands their deal to cover an additional development product. This isn’t just a technical detail. MannKind will see a $5 million upfront payment, has a shot at another $35 million if development milestones are hit, and stands to collect royalties...

Source: Yahoo

9/5/2025

Health care stocks edged higher late Friday afternoon with the NYSE Health Care Index edging up 0.1%

Source: Yahoo

9/5/2025

Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health

Source: Yahoo

9/5/2025

MannKind's (MNKD) game plan of enhancing its revenue base, while also advancing a potential pipeline

Source: Yahoo

9/4/2025

UTHR delivered strong phase 3 TETON-2 results for nebulized Tyvaso in IPF, meeting the primary endpoint and unlocking major catalyst potential. Read the full stock analysis here.

Source: SeekingAlpha

9/4/2025

United Therapeutics (UTHR) Tyvaso inhalation solution likely has "significant" room to be a potentia

Source: Yahoo

9/3/2025

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

Source: Yahoo

9/3/2025

Markets reopened after the Labor Day break on softer footing, with futures tied to the major indexes pointing lower. Investors are balancing several pressures at once: gold prices have surged to fresh record highs above $3,550 an ounce, silver has crossed the $40 mark for the first time since 2011, and bond yields are edging toward 5%. The combination signals an intensifying flight to safety even as equity markets wobble. Oil prices have inched higher, with U.S. crude trading near $66 a barrel a

Source: Yahoo

9/3/2025

Tesla (TSLA) stock is at a crossroads: while Elon Musk highlights the potential growth boost from robotics, pressure mounts amid continued sales slump in Europe and the end of some key US subsidies. Opendoor (OPEN) shares are now up more than 750% in three months, as viral social media posts drive new excitement around the real estate platform. Pharma firms Cytokinetics (CYTK), Ionis (IONS) and United Therapeutics (UTHR) all soar more than 30%.

Source: Yahoo

9/3/2025

About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.

Source: Yahoo